Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Enzyme inactivation by chemical treatment
Reexamination Certificate
2006-01-03
2006-01-03
Meller, Michael (Department: 1654)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Enzyme inactivation by chemical treatment
Reexamination Certificate
active
06982157
ABSTRACT:
The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5 -dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.
REFERENCES:
patent: 4895726 (1990-01-01), Curtet et al.
patent: 6576660 (2003-06-01), Liao et al.
patent: 0 521 471 (1993-01-01), None
patent: 0724877 (1996-08-01), None
patent: 401254624 (1989-10-01), None
patent: 405194209 (1993-08-01), None
patent: WO 99/22728 (1999-05-01), None
Robert H. Knopp, “Drug treatment of lipid disorders”, The New England Journal of Medicine, vol. 341, 1999, p. 498-511.
Kantola et al., “Effect of itraconazole on the pharmacokinetics of atorvastatin”, Clinical Pharmacology & Therapeutics, vol. 64, 1998, p. 58-65.
Neuvonen et al., “Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole”, Clinical Pharmacology & Therapeutics, vol. 63, 1998, p. 332-341.
Neuvonen et al., “Itraconazole drstically increases plasma concentrations of lovastatin and lovastatin acid”, Clinical Pharmacology & Therapeutics, vol. 60, 1996, p. 54-61.
Hunninghake, “HMG CoA reductase inhibitors”, Current Opinion in Lipidology 1992; 3:22-28 (cited in the specification at p. 3, lines 11-12).
Miller et al., “Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)”, Clin Pharmacokinet Feb 1998; 34(2): 155-162.
Williams et al., “Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors”, Clin Pharmacokinet 2002; 41(5): 343-370.
Baba Takahiko
Hutchinson Howard G
Pears John S
Raza Ali
Schneck Dennis
AstraZeneca AB
Meller Michael
Morgan & Lewis & Bockius, LLP
Shionogi & Co. Ltd.
LandOfFree
Drug combinations comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug combinations comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug combinations comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558747